ALEXANDRIA REAL ESTATE EQUITIES RE (ARE)
Sector: Real Estate
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Real Estate
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ARE
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ARE | Prior President and Executive Director of Foundation for the National Institutes of Health (“FNIH”); Founder and Principal of The Freire Group; Chair of the Board of Directors | 71 | ["Founder and Principal of The Freire Group", "senior life sciences executive", "expertise in drug development", "biomedical innovation", "technology commercialization", "science policy", "Former President and Executive Director of the FNIH", "Former President and CEO of the TB Alliance", "Directed the Office of Technology Transfer at NIH"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| EXEL | Independent Director | 71 | ["Training as a scientist","Knowledge and experience in U.S. and global public health","Experience in the biopharmaceutical industry and government healthcare policymaking","Leadership experience in the public sector","Former President and Executive Director, Foundation for the National Institutes of Health","Former President and member of the board of directors of the Albert and Mary Lasker Foundation","Former President and CEO of the TB Alliance","Director of the Office of Technology Transfer at the National Institutes of Health"] | ["Governance Committee","Research & Development Committee"] | 2026 |
| BIIB | Independent Chair (after 2026 Annual Meeting) | 71 | ["Executive Leadership and Business Operations","Drug Development","Healthcare and Pharma Leadership","Finance and Accounting","International Business","Public Board Service","Government and Public Policy","Medicine and Scientific Research","Significant knowledge and experience with respect to medical research","Expertise in pharmaceutical industry and government healthcare policymaking","Strong public policy and government experience"] | ["Compensation and Management Development","Corporate Governance"] | 2026 |